Intech Investment Management LLC Lowers Holdings in Repligen Corporation $RGEN

Intech Investment Management LLC lowered its position in Repligen Corporation (NASDAQ:RGEN) by 93.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,625 shares of the biotechnology company’s stock after selling 49,979 shares during the quarter. Intech Investment Management LLC’s holdings in Repligen were worth $594,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of RGEN. Summitry LLC lifted its holdings in shares of Repligen by 16.3% in the 4th quarter. Summitry LLC now owns 1,741 shares of the biotechnology company’s stock worth $285,000 after buying an additional 244 shares during the period. Hantz Financial Services Inc. increased its stake in shares of Repligen by 120.6% during the fourth quarter. Hantz Financial Services Inc. now owns 1,293 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 707 shares during the period. Swedbank AB bought a new stake in shares of Repligen in the fourth quarter valued at about $4,146,000. Coldstream Capital Management Inc. lifted its stake in Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 101 shares during the period. Finally, Lisanti Capital Growth LLC purchased a new stake in Repligen in the fourth quarter worth about $3,189,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $130.13 on Wednesday. The stock has a 50-day moving average of $119.28 and a two-hundred day moving average of $138.32. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The stock has a market cap of $7.34 billion, a P/E ratio of 144.59, a P/E/G ratio of 2.42 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The firm’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts predict that Repligen Corporation will post 1.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on RGEN. HSBC dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Canaccord Genuity Group cut their price target on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Jefferies Financial Group reiterated a “hold” rating and issued a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Roth Mkm started coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price target on the stock. Finally, Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.